Effect of infliximab combined with methylprednisolone on expressions of NF-κ B, TRADD, and FADD in rat acute spinal cord injury

Spine

Volumn 38, Issue 14, 2013, Pages

  Luo, Chengke ^a   Li, Weiwei ^a   Wang, Xiyang ^a   Wu, Ping ^a   Pang, Xiaoyang ^a   Xu, Zhengquan ^a   Zeng, Hao ^a   Zhang, Penghui ^a   Peng, Wei ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Fadd; Infliximab combinated with methylprednisolone; Nf b; Spinal cord injury; Tradd

Indexed keywords

FAS ASSOCIATED DEATH DOMAIN PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; MESSENGER RNA; METHYLPREDNISOLONE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASSO BETTIE BRESNAHAN LOCOMOTOR RATING SCALE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FUNCTIONAL ASSESSMENT; HINDLIMB; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MOTOR PERFORMANCE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RATING SCALE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPINAL CORD INJURY;

ACUTE DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; METHYLPREDNISOLONE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; NF-KAPPA B; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPINAL CORD; SPINAL CORD INJURIES; TIME FACTORS; TNF RECEPTOR-ASSOCIATED DEATH DOMAIN PROTEIN;

EID: 84880081961     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e318294892c     Document Type: Article

References (34)

1. Priebe MM, Chiodo AE, Scelza WM, et al. Spinal cord injury medicine. 6. Economic and societal issues in spinal cord injury. Arch Phys Med Rehabil 2007; 88 ( suppl 1 ): S84- 8. (Pubitemid 46281868)
2. Esposito E, Cuzzocrea S. Anti-TNF therapy in the injured spinal cord. Trends Pharmacol Sci 2011; 32 : 107- 15.
3. Hulsebosch CE. Recent advances in pathophysiology and treatment of spinal cord injury. Adv Physiol Educ 2002; 26 : 238- 55.
4. Tator CH, Fehlings MG. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J Neurosurg 1991; 75 : 15- 26.
5. Gupta R, Bathen ME, Smith JS, et al. Advances in the management of spinal cord injury. J Am Acad Orthop Surg 2010; 18 : 210- 22.
6. Tohda C, Kuboyama T. Current and future therapeutic strategies for functional repair of spinal cord injury. Pharmacol Ther 2011; 132 : 57- 71.
7. Tobinick E. Perispinaletanercept: a new therapeutic paradigm in neurology. Expert Rev Neurotherapeutics 2010; 10 : 985- 1002.
8. Genovese T, Mazzon E, Crisafulli C, et al. TNF-alpha blockage in a mouse model of SCI: evidence for improved outcome. Shock 2008; 29 : 32- 41.
9. Kurt G, Ergun E, Cemil B, et al. Neuroprotective effects of infl iximab in experimental spinal cord injury. Surg Neurol 2009; 71 : 332- 6, discussion 336.
10. Guven C, Borcek AO, Cemil B, et al. Neuroprotective effects of infliximab in experimental spinal cord ischemic injury. J Clin Neurosc 2010; 17 : 1563- 7.
11. Basso DM, Beattie MS, Bresnahan JC. A sensitive and reliable locomotor rating scale for open fi eld testing in rats. J Neurotrauma 1995; 12 : 1- 21.
12. Hausmann ON. Post-traumatic inflammation following spinal cord injury. Spinal Cord 2003; 41 : 369- 78.
13. Drojdahl N, Fenger C, Nielsen HH, et al. Dynamics of oligodendrocyte responses to anterograde axonal (Wallerian) and terminal degeneration in normal and TNF-transgenic mice. J Neurosci Res 2004; 75 : 203- 17.
14. Kim JM, Cho HH, Lee SY, et al. Role of IRAK1 on TNF-induced proliferation and NF- κ B activation in human bone marrow mesenchymal stem cells. Cell Physiol Biochem 2012; 30 : 49- 60.
15. Licastro F, Chiappelli M, Ianni M, et al. Tumor necrosis factor-alpha antagonists: differential clinicaleffects by different biotechnological molecules. Int J Immunopathol Pharmacol 2009; 22 : 567- 72.
16. Karampetsou MP, Liossis SN, Sfi kakis PP. TNF-alpha antagonists beyond approved indications: stories of success and prospects for the future. QJM: Monthly J Assoc Phys 2010; 103 : 917- 28.
17. Kwon BK, Tetzlaff W, Grauer JN, et al. Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J 2004; 4 : 451- 64. (Pubitemid 38992289)
18. Chen HC, Fong TH, Lee AW, et al. Autophagy is activated in injured neurons and inhibited by methylprednisolone after experimental spinal cord injury. Spine 2012; 37 : 470- 5.
19. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990; 322 : 1405- 11. (Pubitemid 20152525)
20. Bracken MB, Shepard MJ, Collins WF Jr, et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year followup data. Results of the second National Acute Spinal Cord Injury Study. J Neurosurg 1992; 76 : 23- 31.
21. Bracken MB, Shepard MJ, Holford TR, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997; 277 : 1597- 604.
22. Bracken MB, Shepard MJ, Holford TR, et al. Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial. J Neurosurg 1998; 89 : 699- 706. (Pubitemid 28485526)
23. Chappell ET. Pharmacological therapy after acute cervical spinal cord injury. Neurosurgery 2002; 51 : 855- 6; author reply 856. (Pubitemid 36331091)
24. Botelho RV, Daniel JW, Boulosa JL, et al. Effectiveness of methylprednisolone in the acute phase of spinal cord injuries-a systematic review of randomized controlled trials. Rev Assoc Med Bras 2009; 55 : 729- 37.
25. Hurlbert RJ. The role of steroids in acute spinal cord injury: an evidence-based analysis. Spine (Phila Pa 1976) 2001; 26 ( suppl 24 ): S39- 46. (Pubitemid 34019778)
26. Breslin K, Agrawal D. The use of methylprednisolone in acute spinal cord injury a review of the evidence, controversies, and recommendations. Pediatr Emerg Care 2012; 28 : 1238- 48.
27. Bracken MB. Steroids for acute spinal cord injury. Cochrane Database Syst Rev 2012; 1 : CD001046.
28. Grilli M, Memo M. Nuclear factor-kappaB/Rel proteins: a point of convergence of signalling pathways relevant in neuronal function and dysfunction. Biochem Pharmacol 1999; 57 : 1- 7. (Pubitemid 29012490)
29. Paterniti I, Genovese T, Mazzon E, et al. Liver X receptor agonist treatment regulates inflammatory response after spinal cord trauma. J Neurochem 2010; 112 : 611- 24.
30. Kim GM, Xu J, Xu J, et al. Tumor necrosis factor receptor deletion reduces nuclear factor-kappaB activation, cellular inhibitor of apoptosis protein 2 expressionv, and functional recovery after traumatic spinal cord injury. J Neurosci 2001; 21 : 6617- 25. (Pubitemid 32781106)
31. Cao Y, Li G, Wang YF, et al. Neuroprotective effect of baicalin on compression spinal cord injury in rats. Brain Res 2010; 1357 : 115- 23.
32. Wang YR, Liu RY, Wang LC, et al. Effect of Huwentoxin-I on the Fas and TNF apoptosis pathway in the hippocampus of rat with global cerebral ischemia. Toxicon 2007; 50 : 1085- 94.
33. Qiu J, Whalen MJ, Lowenstein P, et al. Upregulation of the Fas receptor death-inducing signaling complex after traumatic brain injury in mice and humans. JNeurosci 2002; 22 ( 9 ): 3504- 11.
34. Davis AR, Lotocki G, Marcillo AE, et al. FasL, Fas, and deathinducing signaling complex (DISC) proteins are recruited to membrane rafts after spinal cord injury. J Neurotr 2007; 24 : 823- 34.